28,870 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 28,870 shares of the company's stock, valued at approximately $1,942,000. Lisanti Capital Growth LLC owned 0.09% of TransMedics Group as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. NBC Securities Inc. purchased a new position in TransMedics Group in the first quarter valued at approximately $25,000. Atlas Capital Advisors Inc. purchased a new position in TransMedics Group in the fourth quarter valued at approximately $31,000. AlphaQuest LLC purchased a new position in TransMedics Group in the fourth quarter valued at approximately $52,000. Rakuten Securities Inc. increased its stake in TransMedics Group by 68.3% in the fourth quarter. Rakuten Securities Inc. now owns 1,355 shares of the company's stock valued at $84,000 after purchasing an additional 550 shares during the last quarter. Finally, Sava Infond d.o.o. purchased a new position in TransMedics Group in the fourth quarter valued at approximately $94,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Anil P. Ranganath sold 686 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the completion of the sale, the insider now directly owns 13,955 shares of the company's stock, valued at $1,950,909. This trade represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Basile sold 6,000 shares of the stock in a transaction on Friday, May 9th. The stock was sold at an average price of $115.63, for a total value of $693,780.00. Following the sale, the director now directly owns 732 shares of the company's stock, valued at approximately $84,641.16. This represents a 89.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,418 shares of company stock valued at $1,512,613. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Price Performance

TMDX stock opened at $131.45 on Friday. The company has a market capitalization of $4.45 billion, a P/E ratio of 96.65 and a beta of 2.10. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The business has a 50 day simple moving average of $118.51 and a 200-day simple moving average of $86.28. The company has a current ratio of 9.10, a quick ratio of 8.32 and a debt-to-equity ratio of 1.92.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.41. The business had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The company's revenue was up 48.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.35 earnings per share. As a group, equities analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on TMDX. Piper Sandler reiterated an "overweight" rating and issued a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Canaccord Genuity Group reiterated a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Finally, Oppenheimer increased their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $127.33.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.